Tag: Occupational Hazards

Effects of COVID-19 pandemic on pediatric anesthesiologists

Editor's Note This survey of members of the Society for Pediatric Anesthesia finds that COVID-19 has affected the personal and professional lives of pediatric anesthesiologists, with women and non-whites disproportionately affected. Of 561 respondents: 21.7% planned to change their clinical responsibilities, and 10.6% planned to decrease their professional working time…

Read More

By: Judy Mathias
January 27, 2021
Share

Survey finds 71% of employees concerned about vaccine side effects

Editor's Note A Welltok survey of 1,000 adults across the US finds that 71% of employees are worried about COVID-19 vaccine side effects, 60% of Americans have a vaccine brand preference, and 52% are worried about the vaccine supply, the January 25 Human Resource Executive reports. Employers, who are seen…

Read More

By: Judy Mathias
January 27, 2021
Share

Pandemic fatigue affecting mitigation efforts

Editor's Note This study, led by researchers from Johns Hopkins University School of Medicine, Baltimore, analyzed survey responses from 7,705 participants between April 1 and November 24, 2020, on their attitudes and resistance toward COVID-19 mitigation efforts. All US regions experienced decreases in COVID-19 mitigation efforts during this time period,…

Read More

By: Judy Mathias
January 26, 2021
Share

FDA revises EUAs for N95 decontamination systems

Editor's Note The Food and Drug Administration on January 21 reissued emergency use authorizations (EUAs) for 10 systems used to decontaminate N95 respirators used by healthcare personnel . The 10 systems are: Michigan State University Decontamination System Technical Safety Services VHP Decontamination System Stryker Sustainability Solutions VHP Decontamination System STERIS…

Read More

By: Judy Mathias
January 26, 2021
Share

CDC: Anaphylactic reactions after first dose of Pfizer-BioNTech vaccine

Editor's Note From December 14 to 23, 2020, after administration of 1,893,360 first doses of the Pfizer-BioNTech COVID-19 vaccine, the Centers for Disease Control and Prevention (CDC) identified 21 case reports of anaphylaxis. Of those, 4 (19%) were hospitalized (including 3 in intensive care), and 17 (81%) were treated in…

Read More

By: Judy Mathias
January 25, 2021
Share

New negative-pressure ventilator to help treat COVID-19 patients

Editor's Note A new negative-pressure ventilatory support device, similar to the “iron lung” used to treat polio patients in the 1950s, provides an additional treatment option for COVID-19 patients, finds this study by researchers in the UK’s Exovent Task Force, formed in March 2020 in response to the COVID-19 pandemic.…

Read More

By: Judy Mathias
January 21, 2021
Share

Study provides evidence that vaccines protect against new COVID-19 variants

Editor's Note A study, led by researchers from Rockefeller University in New York City, finds that volunteers vaccinated with either the Moderna or the Pfizer/BioNTech vaccine will be protected against new variants of the COVID-19 virus. The researchers tested plasma taken from 20 volunteers who had received both doses of…

Read More

By: Judy Mathias
January 21, 2021
Share

Willingness of US adults to get the COVID-19 vaccine

Editor's Note This study led by researchers from the Virginia Commonwealth University, Richmond, finds that COVID-19 vaccine-related messaging should address concerns about the vaccine and its development and reinforce its benefits to increase the willingness of US adults to get the COVID-19 vaccine and to get the vaccine under an…

Read More

By: Judy Mathias
January 20, 2021
Share

45% of adults surveyed considering mental health treatment because of COVID-19

Editor's Note In a Vida Health survey, nearly half of some 2,000 US adults say they have thought about seeking mental health treatment because of the COVID-19 pandemic, according to the January 19 Human Resource Executive. The vast majority (88%) of those surveyed report mental health symptoms, such as: difficulty…

Read More

By: Judy Mathias
January 20, 2021
Share

J&J’s single-dose COVID-19 vaccine has good safety profile

Editor's Note Results from Johnson & Johnson’s early-stage trials for its COVID-19 vaccine showed neutralizing antibodies in all participants who received the vaccine when they were tested at 57 days. The J&J Ad26.COV2.S vaccine is different than the Pfizer-BioNTech and Moderna vaccines in that it is anenovirus-based rather than mRNA-based.…

Read More

By: Judy Mathias
January 19, 2021
Share

Join our community

Learn More
Video Spotlight
Live chat by BoldChat